NCT04164199 2026-03-16
Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies
BeOne Medicines
Phase 3 Enrolling by invitation
BeOne Medicines
M.D. Anderson Cancer Center
Mirati Therapeutics Inc.
Mirati Therapeutics Inc.
BeiGene
University of Birmingham